At the end of the latest market close, Atea Pharmaceuticals Inc. (AVIR) was valued at $26.38. In that particular session, Stock kicked-off at the price of $26.35 while reaching the peak value of $26.6999 and lowest value recorded on the day was $24.20. The stock current value is $24.71.
Recently in News on April 29, 2021, Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19. Phase 3 trial to evaluate efficacy and safety of AT-527, an oral antiviral for treatment of patients with mild to moderate COVID-19 in outpatient setting. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Atea Pharmaceuticals Inc. shares are logging -73.76% during the 52-week period from high price, and 2.32% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $24.15 and $94.17.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1628461 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Atea Pharmaceuticals Inc. (AVIR) recorded performance in the market was -40.86%, having the revenues showcasing -66.15% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 2.18B, as it employees total of 39 workers.
Specialists analysis on Atea Pharmaceuticals Inc. (AVIR)
During the last month, 0 analysts gave the Atea Pharmaceuticals Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 56.79, with a change in the price was noted -4.54. In a similar fashion, Atea Pharmaceuticals Inc. posted a movement of -15.52% for the period of last 100 days, recording 457,103 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for AVIR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Trends and Technical analysis: Atea Pharmaceuticals Inc. (AVIR)
Raw Stochastic average of Atea Pharmaceuticals Inc. in the period of last 50 days is set at 0.83%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 1.35%. In the last 20 days, the company’s Stochastic %K was 2.28% and its Stochastic %D was recorded 2.06%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -40.86%. The shares increased approximately by -32.13% in the 7-day charts and went up by -59.98% in the period of the last 30 days. Common stock shares were lifted by -66.15% during last recorded quarter.